916 related articles for article (PubMed ID: 21481640)
21. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
[TBL] [Abstract][Full Text] [Related]
22. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
[TBL] [Abstract][Full Text] [Related]
23. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012883. PubMed ID: 29164600
[TBL] [Abstract][Full Text] [Related]
24. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
25. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
27. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
28. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
29. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers.
Tiepolt S; Barthel H; Butzke D; Hesse S; Patt M; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):238-44. PubMed ID: 23104671
[TBL] [Abstract][Full Text] [Related]
30. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-β.
Maya Y; Okumura Y; Kobayashi R; Onishi T; Shoyama Y; Barret O; Alagille D; Jennings D; Marek K; Seibyl J; Tamagnan G; Tanaka A; Shirakami Y
Brain; 2016 Jan; 139(Pt 1):193-203. PubMed ID: 26490333
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
[TBL] [Abstract][Full Text] [Related]
32. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
[TBL] [Abstract][Full Text] [Related]
33. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
[TBL] [Abstract][Full Text] [Related]
34. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
[TBL] [Abstract][Full Text] [Related]
35. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
36. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
37. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study.
Seibyl J; Catafau AM; Barthel H; Ishii K; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Takao M; Akatsu H; Murayama S; Bullich S; Mueller A; Koglin N; Schulz-Schaeffer WJ; Hoffmann A; Sabbagh MN; Stephens AW; Sabri O
J Nucl Med; 2016 Jun; 57(6):900-6. PubMed ID: 26823561
[TBL] [Abstract][Full Text] [Related]
38. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
39. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
[TBL] [Abstract][Full Text] [Related]
40. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
